- Tiziana Receives $3.4 Million in Non-Dilutive Funding
- Tiziana Life Sciences to Dose First Patient with Moderate Alzheimer’s Disease with Foralumab
- FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
- Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
- Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
- Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
- Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
- Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
- Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
More ▼
Key statistics
On Wednesday, Tiziana Life Sciences Ltd (TLSA:NAQ) closed at 0.825, -21.43% below its 52-week high of 1.05, set on Jun 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.8999 |
---|---|
High | 0.8999 |
Low | 0.82 |
Bid | 0.80 |
Offer | 0.95 |
Previous close | 0.859 |
Average volume | 231.21k |
---|---|
Shares outstanding | 103.09m |
Free float | 64.55m |
P/E (TTM) | -- |
Market cap | 85.05m USD |
EPS (TTM) | -0.1496 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 17:59 BST.
More ▼